The Mesoblast Ltd (ASX: MSB) share price is in focus after the company reported Ryoncil® net sales of US$30.3 million for the March 2026 quarter, bringing total net revenue since launch to nearly US$100 million.
What did Mesoblast report?
- Net sales for Ryoncil® reached US$30.3 million in the third quarter to March 2026
- Revenue since Ryoncil® launch now approaches US$100 million
- Strong sales growth in February and March offset a seasonal dip in January
- Ryoncil® is the only FDA-approved cell therapy for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD)
What else do investors need to know?
Mesoblast’s first year of Ryoncil® sales has boosted its balance sheet and is helping to fund label extensions and late-stage clinical programs. The company reiterated its leadership role by being first to market with an FDA-approved mesenchymal stromal cell therapy.
Mesoblast will host its first R&D Day in New York on 8 April 2026, where it will outline growth strategies for Ryoncil® and provide updates on its late-stage product pipeline. Investors can join the live webcast or access a replay on the company’s website.
What’s next for Mesoblast?
The company is focusing on expanding Ryoncil®’s approved uses, including studies in adults with SR-aGvHD and in biologic-resistant inflammatory bowel disease. Mesoblast is also progressing clinical development of rexlemestrocel-L for heart failure and chronic low back pain.
Ongoing investment in its product pipeline and global partnerships should ensure Mesoblast stays at the cutting edge of cell therapy for major inflammatory diseases.
Mesoblast share price snapshot
Over the past 12 months, Mesoblast shares have risen 29%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 20% over the same period.
The post Mesoblast shares: Ryoncil® underpins strong earnings growth appeared first on The Motley Fool Australia.
Should you invest $1,000 in Mesoblast Limited right now?
Before you buy Mesoblast Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mesoblast Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Capricorn Metals delivers solid Q3 FY26 gold production and growth update
- Summerset Group Q1 2026 sales rise on robust demand
- Ramelius Resources confirms guidance, strong March quarter gold output
- Bank of Queensland announces $3.7bn loan sale and capital partnership with Challenger
- Guzman y Gomez posts 20% Q3 FY26 sales growth
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.